Ciapavir  (Synonyms: SBI-0953294)

Ciapavir (SBI-0953294) is a HIV-1 latency-reversing agent. Ciapavir reverses latent HIV-1 reservoir in vitro and in vivo without inducing systemic T cell activation or broad cytokine release. Ciapavir degrades cIAP1 and activates non-canonical NF-κB pathway. Ciapavir can be used for the research of HIV-1 infection^[1].

Ciapavir (0.1-10000 nM; 48 h) mediates HIV-1 latency reversal in 2D10 Jurkat cells through activation of the non-canonical NF-κB pathway^[1].
Ciapavir (1-10 μM; 24 h) does not trigger cytokine release or T cell activation in human PBMCs or resting CD4⁺ T cells at concentrations up to 10 μM^[1].
Ciapavir (0.1-10000 nM; 48 h) synergizes with BET inhibitors JQ1 (HY-13030) and I-BET151 (HY-13235) to enhance HIV-1 latency reversal in 2D10 Jurkat cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ciapavir (10-20 mg/kg; i.p.; single dose) demonstrates robust target engagement (cIAP1 degradation) in C57BL/6J mice without triggering significant cytokine release^[1].
Ciapavir (10-20 mg/kg; i.p.; single dose) induces latent HIV-1 expression in antiretroviral therapy-treated BLT mice without overt immune activation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1023.31

C₅₄H₇₀N₈O₈S₂

2433895-70-4

O=C([C@H]1N2[C@](SCC[C@@H](C2=O)NC([C@H](C)NC)=O)([H])CC1(C)C)N[C@@H](C3=CC=CC=C3C4)[C@@H]4OCC#CC#CCO[C@@H]5CC6=CC=CC=C6[C@@H]5NC([C@H]7N8[C@](SCC[C@@H](C8=O)NC([C@H](C)NC)=O)([H])CC7(C)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pache L, et al. Pharmacological activation of non-canonical NF-κB signaling activates latent HIV-1 reservoirs in vivo[J]. Cell Reports Medicine, 2020, 1(3).